Lundbeck hands over former Alzheimer's candidate to privately-owned biotech company

Lundbeck is giving idalopirdine, which it shelved in 2017 following disappointing results for Alzheimer's disease, to Denovo Biopharma, which has in-licensed rights to all indications.

Photo: Stine Bidstrup/ERH

Denovo Biopharma appears to think that Lundbeck's hand-me-downs are quite the treasure trove.

The companies have made a deal that Denovo will be in-licensing rights to the drug candidate idalopirdine, which Lundbeck formerly developed as a treatment for Alzheimer's disease. This drug was officially shelved in 2017 after a failed phase III study towards the end of the previous year, which also caused the company's share price to plummet.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs